XML 99 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings (Loss) per Share
 12 Months Ended
Dec. 31, 2019
Earnings (Loss) per Share
NOTE 18—Earnings (loss) per share:
The net income attributable to Teva and the weighted average number of ordinary shares used in
the
computation of basic and diluted
loss
per share for the years ended December 31, 2019, 2018 and 2017 are as follows:
                         
 
2019
 
  
2018
 
  
2017
 
 
(U.S. $ in millions, except share data)
 
Net income (loss) used for the computation of diluted
loss
per share
  $
 
 
(999
)    $
 
(2,399
 )   $
(16,525
 )
                         
Weighted average number of shares used in the computation of basic
loss
per share
   
1,091
     
1,021
     
1,016
 
Add:
   
     
     
 
                         
Weighted average number of shares used in the computation of diluted
loss
per share
   
1,091
     
1,021
     
1,016
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic earnings and loss per share are computed by dividing net results attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units (“RSUs”)) during the period, net of treasury shares.
In computing dilutive loss per share for the years ended December 31, 2019, 2018 and 2017
,
no account was taken of the potential dilution of the assumed exercise of employee stock options, RSUs and PSUs, amounting to 113 million,
 
51 million and 38 million weighted average shares, respectively, and convertible senior debentures, since they had an anti-dilutive effect on
loss
per share.
Additionally, in computing dilutive
loss
per share for the period between January 1, 2018 and December 17, 2018 and for the year ended December 31, 2017, no account was taken of the potential dilution of the mandatory convertible preferred shares amounting to 74 million and 59 million weighted average shares, respectively, since they had an anti-dilutive effect on loss per share.